

CMPS 6630: Introduction to Computational Biology and Bioinformatics

Experimental Structure
Determination Methods

Fold Recognition - Threading

Differences Between Fold Recognition Algorithms

- **Protein Model and Interaction Description**
The full three-dimensional structure is often simplified
- **Energy Parameterization**
Energy functions not as sophisticated as we'll see in molecular simulation
- **Alignment Algorithms**
Dynamic Programming with Frozen Approximation
Double Dynamic Programming
Monte Carlo Minimization
Branch-and-Bound

Limitations

- Fold Recognition algorithms will return the fold that minimizes the energy function or maximizes the alignment score - but that doesn't mean the identified model is correct.
- Identified model structure is often not as good as in homology modeling

Experimental Structure Determination

Methods

X-Ray Diffraction - *X-Ray Crystallography*

Nuclear Magnetic Resonance Spect.

- *NMR Spectroscopy*

Produce atomic coordinates for most atoms

Objective end-products

XRC produces an electron density map

NMR produces a set of geometric constraints

Objective end-products are interpreted


Structures can have errors (usually small)

For larger proteins (>50-100kDa) XRC is best

Smaller proteins or complexes either ok

Study of dynamics best with NMR

**But constraints on what will crystallize
or dissolve at high concentrations**



Experimental Structure Studies

**Use a
Microscope?**



**Take a
picture?**



To diffract light, wavelength of light must be no larger than the object (or object features)


Visible Light

400-700nm (4000-7000Å)


Atomic Spacing

0.15nm (1.5Å)

← X-rays



X-Ray Crystallography



Problems:



Single molecule is very weak diffractor
We don't know how to build X-ray lenses

Solutions:

Use multiple molecules
Observe scattered diffractions - use the computer as a lens

X-Ray Crystallography


Computer as Lens



X-Ray Crystallography

Protein Crystal

Crystal Lattice




Unit cell - smallest volume element that can fully reproduce the crystal structure via translation only

Goal - determine electron density of the average unit cell


X-Ray Crystallography

Computed electron
density ...








X-Ray Crystallography

Computed electron
density ...
From which we infer
atomic positions



X-Ray Crystallography

- 1) Overview
- ➔ 2) Diffraction Theory
- 3) Protein Crystals
- 4) Collecting Diffraction Data
- 5) 'Solving' Diffraction Data - Phasing
- 6) Electron Density Map
- 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data

Elect. Density Map

Fit Elect. Density Map

Structure

Diffraction Theory


Periodic Functions / Wave Equations

$$f(x) = A \cos 2\pi(hx + \phi) \quad f(x) = A \sin 2\pi(hx + \phi)$$

Fourier theory:

Any **periodic function** can be expressed as a sum of basis periodic functions (infinite sum of *sin* and *cos* terms)

In the Fourier Transform, basis functions consist of *sin* and *cos* with all possible frequencies.



We have a
periodic function!

X-Ray Crystallography

If we sum over all atoms in the crystallographic unit cell:
The diffraction point observed at **S** is

Structure Factor

$$\mathbf{F}(\mathbf{S}) = \sum_{j=1}^n f_j \exp[2\pi i \mathbf{r}_j \cdot \mathbf{S}]$$

resulting mag and
phase of the wave
incident on detector
plate

r: position (xyz)

S: spatial frequency (hkl)
resolution

atomic scattering factor

$$f = \int_{\mathbf{r}} \rho(\mathbf{r}) \exp[2\pi i \mathbf{r} \cdot \mathbf{S}] d\mathbf{r}$$

Although the x-rays are a single frequency, each diffraction point corresponds to a different spatial frequency.

Diffraction follows the FT of the electron density of the crystal.

X-Ray Crystallography

If we sum over all atoms in the crystallographic unit cell:
The diffraction point observed at **S** is

Structure Factor

$$\mathbf{F}(\mathbf{S}) = \sum_{j=1}^n f_j \exp[2\pi i \mathbf{r}_j \cdot \mathbf{S}]$$

resulting mag and
phase of the wave
incident on detector
plate

r: position (xyz)

S: spatial frequency (hkl)
resolution

atomic scattering factor

$$f = \int_{\mathbf{r}} \rho(\mathbf{r}) \exp[2\pi i \mathbf{r} \cdot \mathbf{S}] d\mathbf{r}$$






To reconstruct density:

$$\rho(x, y, z) = \frac{1}{V} \sum_h \sum_k \sum_l |F_{hkl}| e^{\alpha'_{hkl}} e^{-2\pi i(hx+ky+lz)}$$

$$\rho(x, y, z) = \frac{1}{V} \sum_h \sum_k \sum_l |F_{hkl}| e^{-2\pi i(hx+ky+lz - \alpha'_{hkl})}$$

X-Ray Crystallography

- 1) Overview
- 2) Diffraction Theory
- ➔ 3) Protein Crystals
- 4) Collecting Diffraction Data
- 5) 'Solving' Diffraction Data - Phasing
- 6) Electron Density Map
- 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data


Elect. Density Map

Fit Elect. Density Map

Structure

Crystal Growth

2D 'Crystal'




Crystal Growth

Inorganic crystals (ie. NaCl) are very strong
Protein crystals held together with weaker forces

- are ***weak, fragile, and hard to grow***

Not perfect in arrangement



Drenth, 1994





Multiple crystals are needed / consumed in data collection

Not all crystals 'behave' (diffract)

May want *derivative* crystals - with ligand, cofactors, ...

Crystal Growth



Crystal Growth

Crystallization Condition Search

Essentially infinite combination of:

salts, pH-buffers, polymers, organic molecules, temperature

Trial and Error

Use of 'Crystal Screens' (commonly successful conditions)

Use of previous knowledge

Coarse Search followed by Fine Search

Sometimes hit is *never* found

First (Coarse) Screen

0.2M Calcium Chloride dihydrate, HEPES pH 7.5, 28% PEG 4000

0.2M tri-Sodium Citrate dihydrate, Tris Hydrochloride pH 8.5, 30% PEG 4000

Second (Fine) Screen

0.1M Calcium Chloride dihydrate, HEPES pH 7.5, 28% PEG 4000

0.1M Calcium Chloride dihydrate, HEPES pH 7.5, 30% PEG 4000

0.2M Calcium Chloride dihydrate, HEPES pH 7.5, 30% PEG 4000

0.3M Calcium Chloride dihydrate, HEPES pH 7.5, 28% PEG 4000

0.3M Calcium Chloride dihydrate, HEPES pH 7.5, 30% PEG 4000



'Crystal Screen'

from Hampton Research



CRYSTAL SCREEN™ FORMULATION

| Tube Number | Salt | Tube # | Buffer | Tube # | Precipitant |
|-------------|----------------------------|--------|-------------------------------------|--------|-------------------------------|
| 1 | 1.0% w/v 200mM Citric Acid | 1 | 2.1 M Sodium Phosphate dibasic pH 8 | 1 | 30% w/v PEG4000 |
| 2 | 1.0% | 2 | free | 2 | 4.4% w/v Potassium Acetate |
| 3 | 1.0% | 3 | free | 3 | 4.4% w/v Ammonium Phosphate |
| 4 | 1.0% | 4 | 2.1 M HEPES | 4 | 3.2% w/v Ammonium Sulfate |
| 5 | 2.1 M sodium Citrate | 5 | 2.1 M HEPES | 5 | 30% w/v Potassium Diphosphate |
| 6 | 2.1 M sodium Citrate | 6 | 2.1 M HEPES | 6 | 30% w/v Potassium Diphosphate |
| 7 | 2.1 M sodium Citrate | 7 | 2.1 M HEPES | 7 | 1.4% w/v Sodium Acetate |
| 8 | 2.1 M sodium Citrate | 8 | 2.1 M HEPES | 8 | 30% w/v Potassium Diphosphate |
| 9 | 2.1 M sodium Citrate | 9 | 2.1 M HEPES | 9 | 30% w/v Potassium Diphosphate |
| 10 | 2.1 M sodium Citrate | 10 | 2.1 M HEPES | 10 | 30% w/v Potassium Diphosphate |
| 11 | 2.1 M sodium Citrate | 11 | 2.1 M HEPES | 11 | 30% w/v Potassium Diphosphate |
| 12 | 2.1 M sodium Citrate | 12 | 2.1 M HEPES | 12 | 30% w/v Potassium Diphosphate |
| 13 | 2.1 M sodium Citrate | 13 | 2.1 M HEPES | 13 | 30% w/v Potassium Diphosphate |
| 14 | 2.1 M sodium Citrate | 14 | 2.1 M HEPES | 14 | 30% w/v Potassium Diphosphate |
| 15 | 2.1 M sodium Citrate | 15 | 2.1 M HEPES | 15 | 30% w/v Potassium Diphosphate |
| 16 | 2.1 M sodium Citrate | 16 | 2.1 M HEPES | 16 | 30% w/v Potassium Diphosphate |
| 17 | 2.1 M sodium Citrate | 17 | 2.1 M HEPES | 17 | 30% w/v Potassium Diphosphate |
| 18 | 2.1 M sodium Citrate | 18 | 2.1 M HEPES | 18 | 30% w/v Potassium Diphosphate |
| 19 | 2.1 M sodium Citrate | 19 | 2.1 M HEPES | 19 | 30% w/v Potassium Diphosphate |
| 20 | 2.1 M sodium Citrate | 20 | 2.1 M HEPES | 20 | 30% w/v Potassium Diphosphate |
| 21 | 2.1 M sodium Citrate | 21 | 2.1 M HEPES | 21 | 30% w/v Potassium Diphosphate |
| 22 | 2.1 M sodium Citrate | 22 | 2.1 M HEPES | 22 | 30% w/v Potassium Diphosphate |
| 23 | 2.1 M sodium Citrate | 23 | 2.1 M HEPES | 23 | 30% w/v Potassium Diphosphate |
| 24 | 2.1 M sodium Citrate | 24 | 2.1 M HEPES | 24 | 30% w/v Potassium Diphosphate |
| 25 | 2.1 M sodium Citrate | 25 | 2.1 M HEPES | 25 | 30% w/v Potassium Diphosphate |
| 26 | 2.1 M sodium Citrate | 26 | 2.1 M HEPES | 26 | 30% w/v Potassium Diphosphate |
| 27 | 2.1 M sodium Citrate | 27 | 2.1 M HEPES | 27 | 30% w/v Potassium Diphosphate |
| 28 | 2.1 M sodium Citrate | 28 | 2.1 M HEPES | 28 | 30% w/v Potassium Diphosphate |
| 29 | 2.1 M sodium Citrate | 29 | 2.1 M HEPES | 29 | 30% w/v Potassium Diphosphate |
| 30 | 2.1 M sodium Citrate | 30 | 2.1 M HEPES | 30 | 30% w/v Potassium Diphosphate |
| 31 | 2.1 M sodium Citrate | 31 | 2.1 M HEPES | 31 | 30% w/v Potassium Diphosphate |
| 32 | 2.1 M sodium Citrate | 32 | 2.1 M HEPES | 32 | 30% w/v Potassium Diphosphate |
| 33 | 2.1 M sodium Citrate | 33 | 2.1 M HEPES | 33 | 30% w/v Potassium Diphosphate |
| 34 | 2.1 M sodium Citrate | 34 | 2.1 M HEPES | 34 | 30% w/v Potassium Diphosphate |
| 35 | 2.1 M sodium Citrate | 35 | 2.1 M HEPES | 35 | 30% w/v Potassium Diphosphate |
| 36 | 2.1 M sodium Citrate | 36 | 2.1 M HEPES | 36 | 30% w/v Potassium Diphosphate |
| 37 | 2.1 M sodium Citrate | 37 | 2.1 M HEPES | 37 | 30% w/v Potassium Diphosphate |
| 38 | 2.1 M sodium Citrate | 38 | 2.1 M HEPES | 38 | 30% w/v Potassium Diphosphate |
| 39 | 2.1 M sodium Citrate | 39 | 2.1 M HEPES | 39 | 30% w/v Potassium Diphosphate |
| 40 | 2.1 M sodium Citrate | 40 | 2.1 M HEPES | 40 | 30% w/v Potassium Diphosphate |
| 41 | 2.1 M sodium Citrate | 41 | 2.1 M HEPES | 41 | 30% w/v Potassium Diphosphate |
| 42 | 2.1 M sodium Citrate | 42 | 2.1 M HEPES | 42 | 30% w/v Potassium Diphosphate |
| 43 | 2.1 M sodium Citrate | 43 | 2.1 M HEPES | 43 | 30% w/v Potassium Diphosphate |
| 44 | 2.1 M sodium Citrate | 44 | 2.1 M HEPES | 44 | 30% w/v Potassium Diphosphate |
| 45 | 2.1 M sodium Citrate | 45 | 2.1 M HEPES | 45 | 30% w/v Potassium Diphosphate |
| 46 | 2.1 M sodium Citrate | 46 | 2.1 M HEPES | 46 | 30% w/v Potassium Diphosphate |
| 47 | 2.1 M sodium Citrate | 47 | 2.1 M HEPES | 47 | 30% w/v Potassium Diphosphate |
| 48 | 2.1 M sodium Citrate | 48 | 2.1 M HEPES | 48 | 30% w/v Potassium Diphosphate |
| 49 | 2.1 M sodium Citrate | 49 | 2.1 M HEPES | 49 | 30% w/v Potassium Diphosphate |
| 50 | 2.1 M sodium Citrate | 50 | 2.1 M HEPES | 50 | 30% w/v Potassium Diphosphate |



Crystal Growth

Robots and Automation


Robots for **Cloning** (ie. getting your gene into a bacteria)

Robots for **Bacterial growth** and **Protein Expression**


Robots for **Protein Purification**

Robots for **Crystallization**

Robots for **Imaging** (crystal detection)








porter.llnl.gov



X-Ray Crystallography

- 1) Overview
- 2) Diffraction Theory
- 3) Protein Crystals
- ➔ 4) Collecting Diffraction Data
- 5) 'Solving' Diffraction Data - Phasing
- 6) Electron Density Map
- 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data

Elect. Density Map

Fit Elect. Density Map

Structure

X-Ray Sources

Requires high-energy X-ray source

- home sources


- synchrotron (particle accelerators)

Wavelengths: 0.6Å - 1.5Å

Advanced Photon Source at Argonne
(Illinois, USA)

Appx. 3km around





~2-3cm

A


B

D


A: Cryo-stream (-160C)

B: Goniometer


D: Nylon loop




Setup



Diffraction




Diffraction



Diffraction






Amplitudes only!



***How to
determine phases?***

X-Ray Crystallography

- 1) Overview
- 2) Diffraction Theory
- 3) Protein Crystals
- 4) Collecting Diffraction Data
- ➔ 5) 'Solving' Diffraction Data - Phasing
- 6) Electron Density Map
- 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data

Elect. Density Map



Fit Elect. Density Map

Structure


Phasing - MR

Molecular Replacement (MR)

Bootstrap phase determination using phases from homologous structure




Phasing - MR




c Duck intensities
and cat phases

Phasing - MR




c Duck intensities
and cat phases




d Back-transform of *c*

Phasing - MR




a Cat and cat diffraction




b Manx and Manx FT

Phasing - MR




c Cat intensities with
Manx phases

Phasing - MR



c Cat intensities with
Manx phases




d Back-transform of *c*

Model








Phasing - MR



X-Ray Crystallography

- 1) Overview
- 2) Diffraction Theory
- 3) Protein Crystals
- 4) Collecting Diffraction Data
- 5) 'Solving' Diffraction Data - Phasing
- ➔ 6) Electron Density Map
- 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data

Elect. Density Map

Fit Elect. Density Map

Structure

Electron Density Map

We have initial phase estimates, with confidences

$$\rho(x, y, z) = \frac{1}{V} \sum_h \sum_k \sum_l w_{hkl} |F_{\text{obs}}| e^{-2\pi i(hx + ky + lz - \alpha'_{\text{calc}})}$$

Initially we will only have confidence in low frequency / resolution terms


molecular envelope

Improve Map


If $\rho(x, y, z) < 0$
then $\rho(x, y, z) = 0$

Increase overall density
to expected density

New density to
recompute phases




Electron Density Map



Rhodes, 2000

Series truncated at 6.0 Å


Electron Density Map



Rhodes, 2000

Series truncated at 4.5 Å


Electron Density Map



Rhodes, 2000

Series truncated at 3.0 Å




Electron Density Map



Rhodes, 2000





Series truncated at 1.6 Å

Electron Density Map - Tryptophan



X-Ray Crystallography

- 1) Overview
- 2) Diffraction Theory
- 3) Protein Crystals
- 4) Collecting Diffraction Data
- 5) 'Solving' Diffraction Data - Phasing
- 6) Electron Density Map
- ➔ 7) Fitting the Map - Generating the Molecular Structure



Diffraction Data

Elect. Density Map

Fit Elect. Density Map

Structure

Fitting

Phase Extension

Increasing confidence of phases

Iterative incorporation of higher resolution terms

Iterative model building and refinement


Use of difference maps ($F_0 - F_c$)

Molecular Replacement Model

Serves as starting point for manual manipulation (changing A \rightarrow B)

No Model?

Build from scratch



Fitting / Refinement - Typical

1) Early Fittings Often Done Manually

First trace - disconnected, fragments, low resolution

Ridge lines - through regions of maximum density - backbone?

2) Build Backbone from Trace (find C_{α})

3) Align Sequence to the Trace


Find landmarks (ie. characteristic AAs)

4) Place Side-Chains

5) Adjust (refine) Structure

atoms ~4Å apart, near the center of the main-chain next to bulges representing side-chains

Poly-Alanine
if unknown



Phe



Leu



Lys

ARP/wARP

Given an Initial Electron Density Map


- Refine phases
- Build a protein model (structure)

Assumptions:

- Crystal is a protein crystal
 - Long single non-branching polypeptide chain
- Accessibility to high-resolution data (2.3Å)

General Steps:

- Place Dummy Atoms
- Build Skeleton
- Refine Skeleton
- Add Sidechains



ARP/wARP


Flood Electron Density Map with Dummy Atoms

Atoms placed in regions of high electron density

Each placed atom is free to move (untethered)

Moves: translation, appear, disappear

Update phases



ARP/wARP


Flood Electron Density Map with Dummy Atoms

Atoms placed in regions of high electron density


Each placed atom is free to move (untethered)

Moves: translation, appear, disappear

Update phases



ARP/wARP



Atoms usually within 0.5Å of final position

Tasks:

- Identify atom types
- Identify connectivity
- Align to sequence

First: Identify putative C_{α} positions

ARP/wARP


Each C_α should be connected to at least one other C_α approximately 3.8Å away in either:

- C(=O)-N- C_α Forward (outgoing)
- N-C(=O)- C_α Backward (incoming)

For all pairs of atoms $\sim 3.8\text{\AA}$ apart, check intervening electron density

If correlation of electron density is above threshold:

- Make vertex from candidate atoms
- Add edge between atoms



ARP/wARP

Given directed graph (previous slide) of candidate C_a

Generate graph where each vertex represents 4 continuous C_a

Consider all paths of length 4 in original graph

Prune 4-mers that are not consistent with protein structure


Valence Angle

$$C_\alpha(n) - C_\alpha(n+1) - C_\alpha(n+2)$$

Dihedral Angle

$$C_\alpha(n) - C_\alpha(n+1) - C_\alpha(n+2) - C_\alpha(n+3)$$

Underlying distribution mined from
pdb, represented with Parzen
windows of multivariate Gaussians.



ARP/wARP



Optimization problem:

Finding set of chains in a weighted graph with highest score

Vertices - 4 C_a segments

Edges - overlapping fragments


Weights - geometrical scores of fragment and average electron density






- Depth first search from each node to identify 'best' scoring chains
- Greedy merging
- Avg branching factor 2-4

ARP/wARP

Sidechains



Consider atoms neighbouring C_a s but not part of the backbone.
Compute a mini-feature vector for each C_a , based on number
of atoms hanging off the C_a



$$p(\text{AA}|D_i)$$

Compute probability of each
AA type for each C_a density
region D_i

Compute score of sliding window over observed densities D and known
sequence S

$$P(D_i, j) = \prod_{k=-m}^m p(S_{j+k}|D_{i+k})$$

TEXTAL

Locate putative C_a positions

Use of rotation invariant feature vectors


- Average Density / Distance to center of mass
- Moment of Inertia Based, Skewness (magnitudes and ratios)
- Tubes (C_a should have 3 regions of density extending out)

19 Features per Radius (4 radii used)

Compare feature vectors to classify each C_a into

Structure and AA type

Match against fragments from the PDB database




Phe

Leu

Lys

TEXTAL




Holton, Ioerger, Christopher, Sacchettini, 2000

TEXTAL: green structure, top sequence

Correct / Refined: white structure, bottom sequence


TEXTAL



Holton, Joerg, Christopher, Sacchettini, 2000

TEXTAL: white
Correct: blue

TEXTAL




Results Building 12 Proteins

Mean Ca RMSD = 0.96Å

All atom RMSD = 1.04Å

TEXTAL: white
Correct: blue

Iterative Structure Solution - XRC



Nuclear Magnetic Resonance Spect.


Proteins in Solution - high concentration, but don't want crystal

Two broad classes of experiments:

- Get dictionary of resonances
- Measure geometric constraints (bond, angle, space)


Generate ensemble of conformations consistent with constraints

Can measure protein dynamics




Effect of Local Environment

IMPORTANT



Different Atoms
Different Electronic Environments
Atoms experience B_0 differently
Resonate at different frequencies
slightly different frequencies




NMR

Resonance Transfer

Provides Information on:

Connectivity, Torsion Angles, Proximity




NMR

Resonance Transfer

Provides Information on:


Connectivity, Torsion Angles, Proximity




NMR

Assignment Problem!

Spectra are Unassigned!
Unknown correspondence
between spectral peak and
residue




A43
L44
Y45
V46
S47
S48



NMR

Peak Picking Problem!




HSQC

Heteronuclear Single- Quantum Correlation

Through Bond Experiment
Identifies NH Resonances

Cross-Peaks indicate
that atoms are **coupled**
(aka Spin System)



NMR

Three Main Stages

Resonance Assignments (assume peaks picked)

Geometric Constraints

Dihedrals: J-couplings - interaction of dipoles

Interatomic Distances: NOEs

Relative Bond Vector Orientation: RDCs

Structure Generation


2D vs 3D vs ...

Multidimensional NMR

Vary transfer times

Spreads peaks out

Allows better peak picking




NMR - Experiment Types

HSQC - (HN(i), N(i))

HNCA - (HN(i), N(i), C_a(i)) & (HN(i), N(i), C_a(i-1))

HNCOCA - (HN(i), N(i), C_a(i-1))

HNCO, HNCACO, CCONH, CBCACONH, HNCACB




NMR - Experiment Types

HSQC - (HN(i), N(i))

HNCA - (HN(i), N(i), C_a(i)) & (HN(i), N(i), C_a(i-1))


HNCOCA - (HN(i), N(i), C_a(i-1))

HNCO, HNCACO, CCONH, CBCACONH, HNCACB



NMR

Through Space Resonance Transfer




NOESY

Nuclear Overhauser Effect (NOE)
Through Space
Resonance transferred between
two non-bonded hydrogens.
Strength falls off as r^6
Atoms must be $<6\text{\AA}$ apart

NMR

NOESY



Nuclear Overhauser Effect (NOE)
Through Space
Resonance transferred between
two non-bonded hydrogens.
Strength falls off as r^6
Atoms must be $<6\text{\AA}$ apart


Crude Distance Measurements

| | |
|----------------------|-----------|
| Large Peaks | 0 - 2.5 Å |
| Medium Peaks | 0 - 3.5 Å |
| Smaller Peaks | 0 - 5.0 Å |

NMR

Residual Dipolar Couplings

Measures angle of bond vector wrt B_0
Use of partially aligning media



NMR

Available Information

Sequential Connectivity

HSQC, HNCA

Residue Type 'Assignment'

TOCSY

Through Space Distance Constraints

NOEs

Bond Vector Orientations

RDCs

Geometric Constraints

Dihedrals: J-couplings - interaction of dipoles

Interatomic Distances: NOEs

Relative Bond Vector Orientation: RDCs



NMR - Structure Generation

Challenges:

Missing information

False information

Typical Approach: MC or Molec. Dynamics

$$V_{\text{total}} = V_{\text{bonded}} + V_{\text{nonbonded}} + V_{\text{NMR}}$$

DYANA

Start with 'random' conf.

Energy function of PE, KE


Torsion Angle Optimization

MD with Simulated Annealing

$$V = \underbrace{\sum_{u,l,v} \sum_{(\alpha,\beta) \in I_c} f_c(d_{\alpha\beta}, b_{\alpha\beta})}_{\text{distance constraints}} + \underbrace{w_d \sum_{k \in I_d} \left(1 - \frac{1}{2} \left(\frac{\Delta_k}{\Gamma_k} \right)^2 \right)}_{\text{torsion angle constraints}} \Delta_k^2$$

NOE



NMR



SAR-by-NMR

Structure-Activity-Relationship or
Chemical Shift Perturbation



Assists in Ligand Binding and Protein-Protein Interactions




SAR-by-NMR

Structure-Activity-Relationship or
Chemical Shift Perturbation

Assists in Ligand Binding and Protein-Protein Interactions





Assignment Problem

- Noise, Degeneracy
- Often cast as graph algorithm
- Locate Mutually Consistent Information

Structure Generation

- Identify structures consistent with most geometric constraints
- Must ignore some constraints
- Utilize prior knowledge

Interpreting Dynamics Information

- Model time evolution of spin-systems

Experimental Struct. Determination

Advantages

Limitations

XRC

Protein size, Accuracy

Must grow crystals, Limited dynamics information, Rare to see hydrogens, Potentially non-physiologic folds, Phase problem, **Cost, Time**

NMR

Solution (no crystals), Some dynamics information, Some sparse-data applications (ie. folding), More physiologic conditions

Size limits, Isotopic labeling required, Assignment problem, **Cost, Time**


Open Computational Problems:

XRC: cryst condition prediction, phasing, model building and refinement

NMR: pulse sequences, assignment, utilizing novel geometric information (ie. RDCs), model building and refinement

Drug Targets

Biochemical Classes of Drug Targets of Current Therapies



Drug Design

Traditional Drug Design


Identify small molecule capable of binding protein active site and inhibiting protein function

Active Site:


- Small compared with rest of protein
- Three dimensional crevice
- Binding specificity based on functional groups of active site residues (obvious)


Ligand:

Any small, non-protein molecule capable of binding something
Typically <50 atoms
Inhibitors are usually analogs of natural substrate




Reversible Competitive Inhibitor States





Seroquel
(quetiapine)




Lipitor
(atorvastatin)


Tylenol
(acetaminophen)




Aspirin





Taxol




Amoxicillin









Protein-Ligand Interactions



Protein Ligand Binding




Kitchen, Decornez, Furr, Bajorath, Nature Reviews Drug Disc, 2004

$$\Delta G = -RT \ln K_A \quad K_A = \frac{1}{K_D} = \frac{[EI]}{[E][I]}$$

Protein Ligand Binding

Maximum Likelihood


(pick most probable)



Global Minimum Energy
Conformation

Bayesian


(average over all
conformations)



Probability \leftrightarrow *Energy* using
Boltzmann distribution

High Throughput Screening (HTS)

Brute Force




THE NEXT GENERATION IN WORKSTATIONS

From Hamilton, The Leaders in Liquid Handling


SBDD Process



Choice of Protein Target



Docking



If promising

Pre-Clinical Trials



Clinical Trials



Drug



SBDD Approaches

Structure Based Drug Design

Find (or design) a **ligand which will tightly bind** the active site and **determine where the ligand binds**

Input: Model of AS, set of candidate ligands or fragments, energy function

Output: Set of binding ligands with their bound conformations

Issues

Scoring Function


Flexibility (Backbone/Sidechain)

ligand (rigid / flexible)

receptor (rigid / flexible)


Solvent Modeling (explicit/implicit)

usually ignored, why?



Molecular Flexibility

3 'Snapshots' of CBFb



SBDD Approaches


Structure Based Drug Design

Database Search

Docking - Virtual Screening

De Novo Ligand Design

Building vs. Bridging



Database Search

Screen DB of 100,000 molecules - **Dock** ligand into active site

Energy function to evaluate goodness of fit

Ligand score represented by:

Minimum energy over all conformations -

the Global Minimum Energy Conformation (GMEC)

$$\Delta G_{\text{bind}} = \Delta G_P + \Delta G_L + \Delta G_{PL} + \Delta G_{\text{solvent}} + \Delta G_{\text{entropy}}$$

Direct handle to binding strength


Brute Force

6-DOF Search (no internal DOF)

20x20x20Å grid (0.5Å spacing)

100-sample points per rotation axis

$100^3 \times 40^3 = 6.4 \times 10^{10}$ conformations



This is one molecule without
protein or ligand flexibility

Database Search

Docking Search Methods

Random Methods

Monte Carlo / Simulated Annealing

Genetic Algorithms (state variables 'genes')

Tabu Search (avoid previously seen solutions)

Simulation Methods

Molecular Dynamics

Minimization Methods

Energy Minimization (rarely used alone)

Docking Scoring

Empirical Energy function (varying types)

Some with explicit hydrogen-bond terms



Database Search

Ligand Flexibility

Ensemble-Based

Generate multiple conformations of each ligand

Dock each conformation


Compute some consensus score (weighted average)

Explicitly Modeled with Hinges

Maintain information on rotatable dihedrals

Allow them to move during docking

May need to utilize 'rotamers' to get over energy barriers



Protein (Receptor) Flexibility

Systematic modeling not feasible

Some approaches


Explicit Backbone vs Sidechain Flexibility

Dock against **Ensemble** (FlexX, FlexE)

Multiple 'static' conformations

Harmonic (Normal) Mode Analysis

Soft-Receptors (dampen vdW term)



Docking

AutoDock

Search: Lamarckian Genetic Algorithm

Scoring: 5-term Energy Function (with explicit h-bond term)

Ligand Flex: Random search, MC/SA

Receptor Flex: Sidechain Flexibility

Notes: Freely available to academic community

DOCK

Search: GA, First fragment placed via sterics, grow

Scoring: 3 scoring functions (none with explicit h-bond term)

Ligand Flex: Systematic, Fragment-based flexibility (incremental)

Receptor Flex: Limited, Can now dock to ensembles

Notes: Very fast, but limited accuracy, Free to academics

GOLD

Search: Genetic Algorithm

Scoring: Empirical Energy Function (with explicit h-bond term)

Ligand Flex: Random search, GA

Receptor Flex: Limited

Docking

Performance

Decent at *enrichment*

Not so good at absolute binding strength

Most able to predict known protein-ligand poses with
1.5-2Å RMSD 70-80% of the time

Performance drops dramatically with >7 rotatable bonds
Only 20-30% within 1.5-2Å

No major methodology change over past 10 years

Challenges

Scoring function

Solvent modeling

Deterministic search (better branch-bound algorithms)

Micro-Flexibility (Multi-resolution rotamers?)

Macro-Flexibility (NMR?, Harmonic Mode Analysis?)

de novo

General Scheme


- Based on identification and satisfaction of ***interaction sites***
- **Select interaction sites**
- **Satisfy interaction sites** with functional groups
- **Join functional groups** (Bridging technique)
- **Refine structure**

Building Methods (Grow methods)

Start with seed fragment
Selectively add atoms (fragments)


Bridging (Linking) Methods

Dock multiple fragments
Connect by bridging



h-bond donors
h-bond acceptors
electrostatic
hydrophobic



de novo



Define
Binding Pocket

Determine
Interaction Sites

Bridging (Linking) Methods



Building (Grow) Methods

de novo

Major Challenges

- Problems when interaction sites are far away
- Very difficult to model receptor flexibility
- Synthetic accessibility
- Suggested molecules may not be chemically stable
- Pharmacodynamic / Pharmacokinetic properties of ligands

Components / Parameters

Building Blocks: Atoms vs. Fragments

Search Strategy: Deterministic (DFS, BFS), Random (MC, GA)

Construction: Bridging vs. Building

Scoring Function: Empirical Energy Force Field

de novo - Buildup

Monte Carlo de Novo Ligand Generator (MCDNLG)

Building Blocks: Atom


Search Strategy: Random MC

Active Site starts filled with Carbons

Monte Carlo Steps

- Change atom occupancy (on/off)
- Change atom position
- Change bond type (off/single/double)
- Change atom type (C,N,O)
- Rotate/Translate a fragment

*Heuristic Penalties and Rewards
300,000 steps in typical run*

















de novo - Buildup


GROW

Building Blocks: Fragments
Search Strategy: Beam Search

Attach new fragment
Rotate around new bond
Energy minimize

Table I. Current Fragment Library

| | | |
|---|--|--|
|  Acid |  Aldehyde |  Amide |
|  Amine |  Benzene |  Cyclohexane |
|  Cyclopentane |  Ethane |  Ethylene |
|  Hydroxy |  Methyl |  Methylene |
|  Sulfone |  Thiophene | |



de novo - Bridging

SPROUT

Building Blocks: Fragments

Search Strategy: DFS/BFS, A* Search

Find 'target sites'

Known ligand binding site


Manual ligand docking

Multiple Copy Simultaneous Search (MCSS)

Pharmacophore

Generate Skeletons of 3D Fragments

- No notion of element type
- Anchor one vertex of template, rotate (15°) increments
- Continue to add fragments until some fraction of sites linked
- All templates added in all ways
- A* search (branch-and-bound)






de novo

SPROUT

Substitute Real Atoms into Skeleton

- Based on binding character (H-Donor/Acceptor)
- Conformations grouped by common ancestors



Pharmacophores

Pharmacophore:

A molecular framework that carries (phoros) the essential features responsible for a drug's (=pharmacoon's) biological activity -Paul Ehrlich

Useful when


Active Site structure unknown

Have Positive and Negative Ligand Examples



Paul Ehrlich (1854–1915)

3D Pharmacophore



Can Reduce Pharmacophore Matching Problem to Clique

Pharmacophore as Clique




Start with set of Active Molecules

We don't know which functional groups actually

bind nor which distances are favored

Nodes are equivalent functional groups

Edges are between distance consistent functional groups



Leach, Molecular Modeling, 2003

Cliques represent sets of common (mutually consistent) features

Pharmacophore


Constrained Systematic Search

Goal: Identify arrangements of functional groups accessible to all positive binding examples


Determine regions of k dimensional hyperspace accessible for first molecule

For n^{th} molecule, determine torsion angles that place functional groups in allowed regions


Intersect, Maintain common regions



Molecule 1



Molecule 1 and Molecule 2



Extensions

Pharmacokinetics / Pharmacodynamics

ADMET

Absorption
Distribution
Metabolism
Excretion
Toxicity

ADMET problems
kill most drugs



Lead Optimization

Given lead compound (virtual screening, HTS)

Suggest changes to improve binding

May or may not have structure of lead bound active site




Some Successes...




Alzheimer's disease treatment

Molecular modeling, QSAR, molecular shape analysis, and docking played a role in the discovery of donepezil hydrochloride, an acetylcholinesterase inhibitor (18). Eisai markets this compound as Aricept for patients with Alzheimer's disease.




Donepezil




Antibacterial agent

The earliest example of a compound designed using rational techniques, to my knowledge, is norfloxacin. Structural modifications that led the chemists at Kyorin Pharmaceutical Co. to this compound were made with the assistance of QSAR (16). The compound has been on the market since 1983 under various brand names including Macrodon. Spurred by this advance, the 6-fluoroquinolones became a major class of antibacterial agents.




Norfloxacin



Migraine treatment

Zolmitriptan, a drug for migraine, is a 5-HT_{1D} agonist; it was discovered at Wellcome and is marketed by Zeneca under the brand name Zomig. Molecular modeling and the active analogue approach helped define the pharmacophore (21).



Zolmitriptan

Protein Design

Suggest a sequence of amino acids capable of folding into a desired conformation or possessing a desired function

Inverse protein folding problem

Two Problems

De Novo Design


Very Difficult

ReDesign

Use of existing protein (backbone) template

Improve (thermal) stability

Change substrate



Typically Maximum Likelihood:

For each mutation sequence
look for the Global Minimum
Energy Conformation (GMEC)

*Protein design with the use of
rotamers and a pairwise energy
function is NP-Hard*

Dead End Elimination

One of the only deterministic, non-trivial, and effective combinatorial optimization algorithms in Computational Structural Biology

Prunes rotamers that are provably NOT part of the GMEC

Used For

Side-Chain Placement (tertiary structure prediction)
Protein Design


Original DEE

$$E(i_r) + \sum_{j \neq i}^N \min_s E(i_r, j_s) > E(i_t) + \sum_{j \neq i}^N \max_s E(i_t, j_s)$$

Dead End Elimination

Total Energy



$$E_T = \sum_i \sum_j E(i_r, j_s); \quad i < j$$



Dead End Elimination

Total Energy



$$E_T = \sum_i \sum_j E(i_r, j_s); \quad i < j$$



Dead End Elimination

Total Energy



$$E_T = \sum_i \sum_j E(i_r, j_s); \quad i < j$$



Dead End Elimination



Total Energy

$$E_T = \sum_i \sum_j E(i_r, j_s); \quad i < j$$



Dead End Elimination



Original DEE (Simplified)



Dead End Elimination

Original DEE (Simplified)


$$\sum_{j \neq i}^N \min_s E(i_r, j_s) > \sum_{j \neq i}^N \max_s E(i_t, j_s)$$



Dead End Elimination

Original DEE (Simplified)



$$\sum_{j \neq i}^N \min_s E(i_r, j_s) > \sum_{j \neq i}^N \max_s E(i_t, j_s)$$



Dead End Elimination - Extensions

Original DEE (Simplified)


$$E(i_r) + \sum_{j \neq i}^N \min_s E(i_r, j_s) > E(i_t) + \sum_{j \neq i}^N \max_s E(i_t, j_s)$$



Dead End Elimination - Extensions


Original DEE (Simplified)

$$E(i_r) + \sum_{j \neq i}^N \min_s E(i_r, j_s) > E(i_t) + \sum_{j \neq i}^N \max_s E(i_t, j_s)$$



i_r cannot be pruned by i_t or i_u but it can be pruned by i_t AND i_u

A* Search - Conformation Tree



Leach, Lemon. Proteins 33(2):227-39 (1998)


Let $f(x)$ be the score of node x

$$f(x) = g(x) + h(x)$$

$g(x)$ = cost of path from root to node x

$h(x)$ = lower bound on cost of path from x to leaf


A* Search - Conformation Tree



Leach, Lemon. Proteins 33(2):227-39 (1998)

$A_1(21) A_2(108) A_3(206)$

A* Search - Conformation Tree




Leach, Lemon. Proteins 33(2):227-39 (1998)

$A_1(21) A_2(108) A_3(206)$

$A_1B_2(21) A_1B_1(22) A_1B_3(22) A_2(108) A_3(206)$

A* Search - Conformation Tree



Leach, Lemon. Proteins 33(2):227-39 (1998)

$A_1(21) A_2(108) A_3(206)$

$A_1B_2(21) A_1B_1(22) A_1B_3(22) A_2(108) A_3(206)$

$A_1B_2C_2(21) A_1B_1(22) A_1B_3(23) A_1B_2C_1(25) A_2(108) A_3(206)$